Genmab and AbbVie's sBLA for Epkinly Granted FDA Priority Review for Relapsed/Refractory Follicular Lymphoma

Epkinly (epcoritamab-bysp) is a subcutaneously administered, T-cell engaging, immunoglobulin G1-bispecific antibody under evaluation for aggressive B-cell lymphomas.